
Guy Bentley, the Consumer Freedom Director at the American Institute for Economic Research, stated on the institute's website that e-cigarettes not only have lower risks than combustible cigarettes, but are also more effective than FDA-approved nicotine gum and patches.
He believes that the US Food and Drug Administration acknowledged this when it authorized Vuse e-cigarettes in 2021, stating that it recognizes the role of such safer nicotine alternatives in reducing smoking. If the Juul ban is implemented, many Juul users may resort to smoking again, while some smokers who were meant to transition to Juul may continue using traditional cigarettes.
Bentley criticized the FDA for going against its own claim to be acting in the best interest of public health by rejecting Juul's application. A study published in the New England Journal of Medicine found that e-cigarettes are twice as effective as traditional nicotine replacement therapy. This decision also exposes a logical inconsistency in the FDA's recently announced policy to lower nicotine levels in cigarettes to non-addictive levels, as smokers may simply smoke more to compensate for the lower nicotine content.
Bentley stated, "The agency's promise to transition smokers to safer alternatives rings hollow by banning the most popular e-cigarettes among adults.
This article is a compilation of information from third-party sources. Copyright for the compiled information belongs to the original media outlets and authors.
Disclaimer
This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.
Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.
The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.
This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.
Copyright Notice
This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.
No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.
For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.
AI-Assisted Translation and Editing Notice
Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.
Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.










